LB Pharmaceuticals Inc Common Stock

Day range

$38.45 – $41.05

Open

$39.07

Prev close

$38.73

Volume

275.98K

Market cap

$1.25B

Shares out

32.26M

P/E

—

P/S

—

P/B

3.76

P/FCF

—

ROE

-25.8%

ROA

-23.7%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Executive officer appointmentSep 15, 2026

  On September 15, 2026, LB Pharmaceuticals Inc ... announced that Susan G. Kozauer, M.D. has been appointed to serve as the Company's Chief Medical Officer, effective as of September 14, 2026.

• Executive compensation changeSep 3, 2026

  Pursuant to the Employment Agreement, Mr. Miller is entitled to an initial annual base salary of $530,000 (the "Annual Base Salary") and an annual discretionary bonus with a target amount equal to 40% of his annual base salary (the "Target Bonus").

• Private placementJul 29, 2026

  On July 28, 2026, LB Pharmaceuticals Inc (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain investors (the "Investors") pursuant to which the Company, in a private placement (the "Private Placement"), agreed to issue and sell to the Investors an aggregate of (i) 3,577,560 shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock") and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 715,513 shares of Common Stock.

• Executive compensation changeJun 10, 2026

  Pursuant to the Separation Agreement, if Dr. Eramo remains engaged as a consultant and complies with her obligations to the Company through the end of the Consulting Period, she will be entitled to (a) her current base salary on a monthly basis until June 15, 2027, (b) 100% of her target annual bonus for 2026 on a prorated basis, and (c) the acceleration of her outstanding stock options such that 66,143 of the unvested shares subject to the her stock options shall be vested and exercisable on September 15, 2026.

• Executive compensation changeMar 16, 2026

  In connection with Mr. Prensky's separation from the Company, the Company and Mr. Prensky entered into an Amendment No. 1 to Transition, Separation, and Consulting Agreement (the "Transition Agreement Amendment"), effective June 3, 2026, which amended that certain Transition, Separation, and Consulting Agreement, dated November 26, 2024 (the "Transition Agreement"). Pursuant to the Transition Agreement Amendment, Mr. Prensky will continue to provide consulting services as may be reasonably requested by the Company and receive the benefits described in the Transition Agreement. In addition, Mr. Prensky's outstanding and unvested stock options are eligible to continue to vest for the duration of the term of the Transition Agreement Amendment.

Days to cover

14.5

Short interest

6.01M

Avg volume

414.3K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
  positiveGlobeNewswire Inc.· Oct 9, 2026
• LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
  positiveGlobeNewswire Inc.· Jul 22, 2026
• LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
  positiveGlobeNewswire Inc.· Jul 10, 2026
• Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
  positiveBenzinga· Feb 27, 2026
• LB Pharmaceuticals Announces $100.0 Million Private Placement
  positiveGlobeNewswire Inc.· Feb 5, 2026